[go: up one dir, main page]

IL163781A0 - Purine derivatives as kinase inhibitors - Google Patents

Purine derivatives as kinase inhibitors

Info

Publication number
IL163781A0
IL163781A0 IL16378103A IL16378103A IL163781A0 IL 163781 A0 IL163781 A0 IL 163781A0 IL 16378103 A IL16378103 A IL 16378103A IL 16378103 A IL16378103 A IL 16378103A IL 163781 A0 IL163781 A0 IL 163781A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
purine derivatives
purine
derivatives
formula
Prior art date
Application number
IL16378103A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL163781A0 publication Critical patent/IL163781A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
IL16378103A 2002-03-05 2003-03-04 Purine derivatives as kinase inhibitors IL163781A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36224502P 2002-03-05 2002-03-05
PCT/US2003/005050 WO2003076442A1 (en) 2002-03-05 2003-03-04 Purine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL163781A0 true IL163781A0 (en) 2005-12-18

Family

ID=27805149

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16378103A IL163781A0 (en) 2002-03-05 2003-03-04 Purine derivatives as kinase inhibitors
IL163781A IL163781A (en) 2002-03-05 2004-08-26 Purine derivatives as kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163781A IL163781A (en) 2002-03-05 2004-08-26 Purine derivatives as kinase inhibitors

Country Status (16)

Country Link
US (4) US7491716B2 (xx)
EP (1) EP1483265B1 (xx)
JP (1) JP4414232B2 (xx)
KR (1) KR100974770B1 (xx)
CN (1) CN1312154C (xx)
AT (1) ATE346070T1 (xx)
AU (1) AU2003215325B8 (xx)
BR (1) BR0308243B1 (xx)
CA (1) CA2477967C (xx)
CY (1) CY1109006T1 (xx)
DE (1) DE60309848T2 (xx)
DK (1) DK1483265T3 (xx)
ES (1) ES2276048T3 (xx)
IL (2) IL163781A0 (xx)
PT (1) PT1483265E (xx)
WO (1) WO2003076442A1 (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040091113A (ko) * 2002-03-08 2004-10-27 일라이 릴리 앤드 캄파니 피롤-2,5-디온 유도체 및 ｇｓｋ-3 억제제로서 그의 용도
GB0212049D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
RU2547148C2 (ru) 2005-02-09 2015-04-10 Аркьюл, Инк. Композиции и способы лечения рака
ATE542535T1 (de) * 2005-05-04 2012-02-15 Develogen Ag Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DK2383271T3 (da) * 2006-03-13 2013-10-07 Kyorin Seiyaku Kk Aminoquinoloner som GSK-3-inhibitorer
EP1845098A1 (en) 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101302216B (zh) * 2007-05-11 2011-08-10 上海睿智化学研究有限公司 稠环吲哚类化合物的制备方法
EP2392574B1 (en) 2007-06-22 2013-12-18 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
LT2824100T (lt) * 2008-07-08 2018-05-10 Incyte Holdings Corporation 1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8802668B2 (en) * 2009-04-14 2014-08-12 Eli Lilly And Company Hematopoietic neoplasm chemotherapy
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EA020847B1 (ru) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
AU2011208530A1 (en) 2010-01-19 2012-08-09 Astrazeneca Ab Pyrazine derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TWI525091B (zh) * 2010-12-23 2016-03-11 亞闊股份有限公司 吡咯並喹啉基－吡咯啶－２，５－二酮組成物類及製備和使用彼等之方法
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
WO2014098000A1 (en) * 2012-12-17 2014-06-26 Daiichi Sankyo Company, Limited Process for preparation of a tricyclic heterocycle
EP3015468A4 (en) 2013-06-26 2017-02-22 Daiichi Sankyo Co., Ltd. Method for producing tricyclic heterocyclic compound
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2017386417B2 (en) * 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3609998A1 (en) 2017-04-11 2020-02-19 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2019126686A1 (en) * 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
US20200121681A1 (en) 2018-10-17 2020-04-23 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN112390794B (zh) * 2019-08-19 2023-05-26 鲁南制药集团股份有限公司 一种米诺膦酸关键中间体的制备方法
CN115925622A (zh) * 2023-02-10 2023-04-07 山西永津集团有限公司 一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
CN115974850B (zh) * 2023-02-16 2024-08-06 中国药科大学 一类作为akr1c3抑制剂的化合物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DE60010934T2 (de) * 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
RU2003104796A (ru) 2000-07-27 2004-08-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 3-индолил-4-фенил-1н-пиррол-2, 5-диона в качестве ингибиторов гликогенсинтазы-киназы-3 бета
DE60112611T2 (de) 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
ES2263681T3 (es) 2000-12-08 2006-12-16 Ortho-Mcneil Pharmaceutical, Inc. Compuestos de pirrolina indazolil-substituidos como inhibidores de la kinasa.

Also Published As

Publication number Publication date
US20090105229A1 (en) 2009-04-23
US7491716B2 (en) 2009-02-17
KR20040087338A (ko) 2004-10-13
US8022065B2 (en) 2011-09-20
CN1639165A (zh) 2005-07-13
CA2477967A1 (en) 2003-09-18
AU2003215325B2 (en) 2008-09-18
CY1109006T1 (el) 2014-07-02
IL163781A (en) 2010-04-15
EP1483265B1 (en) 2006-11-22
US20110294792A1 (en) 2011-12-01
BR0308243B1 (pt) 2014-08-26
US20050090483A1 (en) 2005-04-28
US8058425B2 (en) 2011-11-15
BR0308243A (pt) 2005-01-11
DK1483265T3 (da) 2007-03-19
US20110207721A1 (en) 2011-08-25
CN1312154C (zh) 2007-04-25
AU2003215325A1 (en) 2003-09-22
CA2477967C (en) 2010-08-10
DE60309848T2 (de) 2007-05-16
ES2276048T3 (es) 2007-06-16
EP1483265A1 (en) 2004-12-08
JP2005526072A (ja) 2005-09-02
DE60309848D1 (de) 2007-01-04
KR100974770B1 (ko) 2010-08-06
AU2003215325B8 (en) 2008-10-09
WO2003076442A1 (en) 2003-09-18
ATE346070T1 (de) 2006-12-15
JP4414232B2 (ja) 2010-02-10
PT1483265E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
IL163781A0 (en) Purine derivatives as kinase inhibitors
IL163777A0 (en) Kinase inhibitors
PL1761520T3 (pl) Inhibitory kinazy
IL160915A0 (en) Indolizines inhibiting kinase proteins
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
PL373645A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
GB0100889D0 (en) Compounds
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
TNSN08191A1 (en) Kinase inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
UA85505C2 (xx) Інгібітори кінази$ингибиторы киназы
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
GB0308201D0 (en) Novel compounds
AU2003268464A8 (en) Indole-type derivatives as inhibitors of p38 kinase
TW200628153A (en) Novel compounds
DOP2005000117A (es) Inhibidores de quinasa
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze